Dr. Pili on Significance of Entinostat/IL-2 Study in RCC
Roberto Pili, MD, professor of Medicine and Robert Wallace Miller Professor of Oncology at Indiana University School of Medicine and a researcher at the Indiana University Melvin and Bren Simon Cancer Center, discusses the significance of the preliminary results of a phase I/II study, which examined the combination of the HDAC inhibitor entinostat and high-dose interleukin-2 (IL-2) in patients with previously untreated metastatic renal cell carcinoma (RCC) of clear cell histology.
Roberto Pili, MD, professor of Medicine and Robert Wallace Miller Professor of Oncology at Indiana University School of Medicine and a researcher at the Indiana University Melvin and Bren Simon Cancer Center, discusses the significance of the preliminary results of a phase I/II study, which examined the combination of the HDAC inhibitor entinostat and high-dose interleukin-2 (IL-2) in patients with previously untreated metastatic renal cell carcinoma (RCC) of clear cell histology.
Out of the 41 evaluable patients with measurable disease, a 37% overall response rate was observed with the combination. Three patients achieved complete remissions and 12 patients achieved objective response.
To date, in patients treated with the combination of entinostat and IL-2, the median progression-free survival was 16.1 months and an overall survival of 65.3 months.
